Tumor cell heterogeneity

Experimental Oncology

Volumn 35, Issue 3, 2013, Pages 154-162

  Chekhun, V F ^a   Sherban, S D ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Epigenetic factors; Genetic instability; Heterogeneity; Malignant phenotype; Metastasis; Primary tumor

Indexed keywords

ALKYLATING AGENT; CATALASE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; HISTONE; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; RNA; SUPEROXIDE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; BIOTINYLATION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL GROWTH; CELL HETEROGENEITY; CHROMATIN STRUCTURE; CPG ISLAND; DNA METHYLATION; DNA REPLICATION; DRUG SENSITIVITY; EPIGENETICS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENOMIC INSTABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; IMMUNE RESPONSE; METASTASIS; ONCOGENE RAS; OXIDATION REDUCTION REACTION; PHENOMENOLOGY; PHENOTYPE; PRIMARY TUMOR; PROTEIN PROCESSING; RADIOSENSITIVITY; REVIEW; SUMOYLATION; TUMOR MICROENVIRONMENT; X CHROMOSOME INACTIVATION;

ANIMALS; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 84892175576     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Shipitsin M, Campbell LL, Argani PS, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-73
2. Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259-65
3. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-22
4. Inda M, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-40
5. Snijder B, Pelkmans L. Origins of regulated cell-to-cell variability. Nature Rev Mol Cell Biol 2011; 12: 119-25
6. Rohwer N, Zasada C, Kempa S, Cramer T. The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond. Oncogene 2013; 32: 3569-76
7. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-35
8. Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011; 112: 255-81
9. Berezhnaya NM. Role of immune system cells in tumor microenvironment. 1. Cells and cytokines - the components of inflammation. Oncology 2009; 11: 6-17 (in Russian)
10. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Ann Rev Pathol 2013; 8: 277-302
11. Tisty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-50
12. Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008; 135: 510-23
13. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev Cancer 2009; 9: 265-73
14. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta Rev Cancer 2009; 1796: 75-90
15. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010; 101: 293-9
16. Deichman GI. Natural selection and early phenotypic changes of tumor cells in vivo: acquisition of new defence mechanisms. Biokhimiya 2000; 65: 92-111 (in Rissian)
17. Shen H, Kauvar L,Tew KD. Importance of glutathion and associated enzymes in drug response. Oncol Res 1997; 9: 295-302
18. Parmigiani G, Boca S, Lin J, et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009; 93: 17-21
19. Weigelt B, Glas AM, Lodewyk FA, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003; 100: 15901-5
20. Campbell LL, Polyak K. Breast tumor heterogeneity. Cell Cycle 2007; 6: 2332-8
21. Elowitz MB, Levine AJ, Siggia ED, Swain PS. Stochastic gene expression in a single cell. Science 2002; 297: 1129-31
22. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7
23. Fishel R, Lescoe MK, Rao MRS, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38
24. Leach FS, Nicolaides NC, Paoadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-25
25. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-T:A mutations in colorectal tumors. Nat Genet 2002; 30: 227-32
26. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386: 761-3
27. Campisi J. Aging, tumor suppression and cancer. Mech Ageing Dev 2005; 26: 51-8
28. van Heemst D, den Reijer PM, Westendorp RGJ. On the role of caretakers and gatekeepers. Eur J Cancer 2007; 43: 2144-52
29. Negrini S,Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-8
30. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011; 11: 450-7
31. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13
32. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6
33. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12
34. Ding D, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75
35. Galvan A, Ioannidis JPA, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010; 26: 132-41
36. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 2008; 5th edition, Garland Science
37. Berger SI, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev 2009; 23: 781-83
38. Ptashne M. On the use of the word "epigenetic". Curr Biol 2007; 17: R233-6
39. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36
40. Pogribny IP. Epigenetic events in tumorigenesis: putting the pieces together. Exp Oncol 2010; 32: 132-6
41. Murra R. Interplay between different epigenetic modifications and mechanisms. Adv Genet 2010; 70: 101-41
42. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010; 70: 27-56
43. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10: 805-11
44. Wild L, Flanagan JM. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim.Biophys Acta RevCancer 2010; 1806: 50-7
45. Feinberg AP, Ohisson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33
46. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011; 30: 3391-403
47. Avvakumov N, Côté J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007; 26: 5395-407
48. Murr R. Interplay between different epigenetic modifications and mechanisms. Adv Genet 2010; 70: 101-41
49. Kim JH, Kim B, Cai L, et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 2005; 434: 921-6
50. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappa B activation. Cancer Sci 2008; 99: 836-42
51. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15: 425-30
52. Lia F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta Rev Cancer 2010; 1805: 167-80
53. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32
54. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-02
55. Eldar A, Elowitz MB. Functional roles for noise in genetic circuits. Nature 2010; 467: 167-73
56. Quaranta V, Garbett SP. Not all noise is waste. Nat Methods 2010; 7: 269-72
57. Raj A, van Oudenaarden A. Single-molecule approaches to stochastic gene expression. Annu Rev Biophys 2009; 38: 255-70
58. Grant V. The evolutionary process. 1991. Moscow: Mir, 488 p. (in Russian)
59. Bregeon D, Doetsch PW. Transcriptional mutagenesis: causes and involvement in tumour development. Nat Rev Cancer 2011; 11: 218-27
60. Schreiber H. Tumor immunology. In: Fundamental Immunology. 3-rd Ed. W.E.Paul, ed. New York: Raven Press Ltd, 1993: 1143-78
61. Furata E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta Rev Cancer 2010; 1805: 141-52
62. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12
63. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13
64. Wiedemeyer R, Brennan C, Heffernan TP, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 2008; 13: 355-64
65. Boyd LK, Mao X, Lu Y-J. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 2012; 9: 652-64
66. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011; 121: 3810-8
67. Weinberg RA. Coevolution in the tumor microenvironment. Nat Genet 2008; 40: 494-5
68. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013; 339: 1546-58
69. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-9
70. Xu X, Hou Y, Yin X, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012; 148: 886- 95
71. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92
72. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96
73. Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714-9
74. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88
75. Durrett R, Moseley S. Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol 2010; 77: 42-8
76. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40
77. Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013; 13: 365-76
78. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27: Abstr 4509
79. Philchenkov AA. Visualization and assessment of treatment-related apoptosis in tumors: clinical perspectives. Oncology 2011;13: 266-77 (in Russian)
80. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610-7